A detailed history of Long Focus Capital Management, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 719,604 shares of AKRO stock, worth $38.9 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares
719,604
Previous 719,604 -0.0%
Holding current value
$38.9 Million
Previous $16.9 Million 22.3%
% of portfolio
0.76%
Previous 0.68%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$18.31 - $24.62 $7.16 Million - $9.63 Million
391,000 Added 118.99%
719,604 $16.9 Million
Q1 2024

May 14, 2024

SELL
$17.76 - $31.18 $3.22 Million - $5.66 Million
-181,396 Reduced 35.57%
328,604 $8.3 Million
Q4 2023

Feb 14, 2024

BUY
$11.38 - $50.33 $4.17 Million - $18.4 Million
366,000 Added 254.17%
510,000 $11.9 Million
Q2 2023

Aug 14, 2023

SELL
$36.89 - $56.88 $737,800 - $1.14 Million
-20,000 Reduced 12.2%
144,000 $6.72 Million
Q1 2023

May 17, 2023

BUY
$37.27 - $50.24 $3.77 Million - $5.08 Million
101,096 Added 160.71%
164,000 $6.27 Million
Q1 2023

May 12, 2023

SELL
$37.27 - $50.24 $3.77 Million - $5.08 Million
-101,096 Reduced 61.64%
62,904 $2.41 Million
Q4 2022

Feb 13, 2023

SELL
$33.44 - $54.8 $4.28 Million - $7.01 Million
-128,000 Reduced 43.84%
164,000 $8.99 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $20,300 - $68,100
2,000 Added 0.69%
292,000 $9.94 Million
Q2 2022

Aug 12, 2022

BUY
$8.0 - $15.01 $2.32 Million - $4.35 Million
290,000 New
290,000 $2.74 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.51B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Long Focus Capital Management, LLC Portfolio

Follow Long Focus Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.